title: Gene polymorphisms as predictors of response to biological therapies in psoriasis patients.
abstract: Psoriasis is a chronic inflammatory autoimmune skin disease, characterized by the formation of erythematous scaly plaques on the skin and joints. The therapies for psoriasis are mainly symptomatic and sometimes with poor response. Response among patients is very variable, especially with biological drugs (adalimumab, etarnecept, infliximab and ustekimumab). This variability may be partly explained by the effect of different genetic backgrounds. This has prompted the investigation of many genes, such as FCGR3A, HLA, IL17F, IL23R, PDE3A-SLCO1C1, TNFα and other associated genes, as potential candidates to predict response to the different biological drugs used for the treatment of psoriasis. In this article, we will review the influence of gene polymorphisms investigated to date on response to biological drugs in psoriasis patients.
authors.affiliation: Pharmacogenetics Unit, UGC Provincial de Farmacia de Granada, Instituto de Investigación Biosanitaria de Granada, Complejo Hospitalario Universitario de Granada, Avda. Fuerzas Armadas, 2, Granada 18014, Spain. Electronic address: teresamaria712@gmail.com.
authors.forename: Teresa María
authors.initials: TM
authors.lastname: Linares-Pineda
authors.affiliation: Pharmacogenetics Unit, UGC Provincial de Farmacia de Granada, Instituto de Investigación Biosanitaria de Granada, Complejo Hospitalario Universitario de Granada, Avda. Fuerzas Armadas, 2, Granada 18014, Spain. Electronic address: marisacgarre@gmail.com.
authors.forename: Marisa
authors.initials: M
authors.lastname: Cañadas-Garre
authors.affiliation: Faculty of Pharmacy, University of Granada, Campus Universitario de Cartuja, s/n, 18071 Granada, Spain. Electronic address: sanchezpster@gmail.com.
authors.forename: Antonio
authors.initials: A
authors.lastname: Sánchez-Pozo
authors.affiliation: Pharmacogenetics Unit, UGC Provincial de Farmacia de Granada, Instituto de Investigación Biosanitaria de Granada, Complejo Hospitalario Universitario de Granada, Avda. Fuerzas Armadas, 2, Granada 18014, Spain. Electronic address: mangel.calleja.sspa@juntadeandalucia.es.
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Calleja-Hernández
mesh_terms: D000818:Animals; D001688:Biological Products / Q000627:therapeutic use*; D001691:Biological Therapy / Q000379:methods; D006801:Humans; D011110:Polymorphism, Genetic / Q000235:genetics*; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics*
chemical_list: D001688:Biological Products
keywords: Adalimumab; Drugs therapies; Effectiveness; Etarnecept; Infliximab; Polymorphisms; Psoriasis; Ustekinumab